Current options of insulin resistence correction in patients with metabolic syndrome

To study thiasolidindion drug pioglitazone for efficacy in metabolic syndrome (MS). Twenty patients with MS were examined at baseline and after 12 week therapy with pioglitazone. The examination included estimation of fasting and postprandial glycemia, insulin resistance index, HOMA-IR index, HbAlc,...

Full description

Saved in:

Bibliographic Details
Published in:	Terapevtic̆eskii arhiv Vol. 78; no. 10; p. 36
Main Authors:	Demidova, T Iu, Ametov, A S, Titova, O I
Format:	Journal Article
Language:	Russian
Published:	Russia (Federation) 2006
Subjects:	Albuminuria - epidemiology Endothelium, Vascular - physiopathology Fasting Female Humans Hypoglycemic Agents - therapeutic use Intra-Abdominal Fat - metabolism Male Metabolic Syndrome - drug therapy Metabolic Syndrome - epidemiology Metabolic Syndrome - physiopathology Middle Aged Obesity - epidemiology Obesity - metabolism Thiazolidinediones - therapeutic use
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	To study thiasolidindion drug pioglitazone for efficacy in metabolic syndrome (MS). Twenty patients with MS were examined at baseline and after 12 week therapy with pioglitazone. The examination included estimation of fasting and postprandial glycemia, insulin resistance index, HOMA-IR index, HbAlc, lipid profile, microalbuminuria (MAU), blood pressure, endothelium-related vasodilation. Pioglitazone therapy for 12 weeks significantly reduced HbAlc, fasting and postprandial glycemia, insulinemia, HOMA-IR, improved blood lipid spectrum, reduced visceral obesity. Positive effects were also achieved on blood pressure, MAU and endothelium-related vasodilation.
ISSN:	0040-3660